A Phase 1 interventional study of AP303 50 μg and AP303 150 μg in Healthy Subjects, sponsored by Alebund Pty Ltd. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-30.
Sponsored by Alebund Pty Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-center, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered AP303 will be assessed in healthy adult subjects.
The study will consist of 2 parts: Part A is a single ascending doses (SAD) phase enrolling a total of 4 cohorts of healthy subjects; Part B is a multiple ascending doses (MAD) phase enrolling 3 cohorts of healthy subjects. One cohort of Part A will receive AP303 under both fasted and fed conditions to investigate the effect of food.
Alebund Pty Ltd is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AP303
Drug: AP303 50 μg · Drug: AP303 150 μg · Drug: AP303 300 μg · Drug: AP303 600 μg
Placebo
Drug: Placebo 50 μg · Drug: Placebo 150 μg · Drug: Placebo 300 μg · Drug: Placebo 600 μg
AP303 tablet
AP303 tablet
AP303 tablet
AP303 tablet
Placebo tablet
Placebo tablet
Placebo tablet
Placebo tablet
Single Dose and Food Effect Safety Outcome Measures
Incidence and severity of adverse events (AEs), laboratory, ECG, and vital sign changes
Time frame: From baseline to Day 14 (Day 29 for Food Effect)
Multiple Dose Safety Outcome Measures
Incidence and severity of AEs, laboratory, ECG, and vital sign changes.
Time frame: From baseline to Day 28
Cmax after single dose
PK characteristics after single dose
Time frame: Pre-dose to 96 hours post-dose
Tmax after single dose
PK characteristics after single dose
Time frame: Pre-dose to 96 hours post-dose
AUC0-last after single dose
PK characteristics after single dose
Time frame: Pre-dose to 96 hours post-dose
AUC0-inf after single dose
PK characteristics after single dose
Time frame: Pre-dose to 96 hours post-dose
t1/2 after single dose
PK characteristics after single dose
Time frame: Pre-dose to 96 hours post-dose
CL/F after single dose
PK characteristics after single dose
Time frame: Pre-dose to 96 hours post-dose
Ae and CLR (if warranted) after single dose
PK characteristics after single dose
Time frame: Pre-dose to 96 hours post-dose
V/F after single dose
PK characteristics after single dose
Time frame: Pre-dose to 96 hours post-dose
Cmax after multiple dose
PK characteristics after multiple dose
Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14
Tmax after multiple dose
PK characteristics after multiple dose
Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14
AUC0-τ after multiple dose
PK characteristics after multiple dose
Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14
Cav after multiple dose
PK characteristics after multiple dose
Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14
t1/2 after multiple dose
PK characteristics after multiple dose
Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14
Rac after multiple dose
PK characteristics after multiple dose
Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14
Ae and CLR (if warranted) after multiple dose
PK characteristics after multiple dose
Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14
V/F after multiple dose
PK characteristics after multiple dose
Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14
Ctrough after multiple dose
PK characteristics after multiple dose
Time frame: Pre-dose on Days 2, 3, 4, 5, 7, 12, and 13
Effect of Food on the single dose Cmax
Effect of food on the single dose PK
Time frame: Pre-dose to 96 hours post-dose
Effect of Food on the single dose Tmax
Effect of food on the single dose PK
Time frame: Pre-dose to 96 hours post-dose
Effect of Food on the single dose AUC0-last
Effect of food on the single dose PK
Time frame: Pre-dose to 96 hours post-dose
Effect of Food on the single dose AUC0-inf
Effect of food on the single dose PK
Time frame: Pre-dose to 96 hours post-dose
Effect of Food on the single dose t1/2
Effect of food on the single dose PK
Time frame: Pre-dose to 96 hours post-dose
Effect of Food on the single dose CL/F
Effect of food on the single dose PK
Time frame: Pre-dose to 96 hours post-dose
Effect of Food on the single dose Ae and CLR (if warranted)
Effect of food on the single dose PK
Time frame: Pre-dose to 96 hours post-dose
Effect of Food on the single dose V/F
Effect of food on the single dose PK
Time frame: Pre-dose to 96 hours post-dose
Ran from Dec 2022 to primary completion in Jul 2023, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AP303
Alebund Pty Ltd